Discovery and Characterization of Benzamide Derivatives as Highly Potent SUCNR1 Antagonists for Cancer Immunotherapy
as a lead candidate for targeting SUCNR1 but also provides compelling evidence for SUCNR1 antagonism as a potent therapeutic approach in immuno-oncology.
Authors
- M Liu
- Changyao Li (ORCID: https://orcid.org/0000-0002-7125-4820)
- Naijipu Abuduaini (ORCID: https://orcid.org/0009-0005-7849-7648)
- Weiqiang Lü (ORCID: https://orcid.org/0000-0003-1349-6597)
- Zhiyuan Cheng (ORCID: https://orcid.org/0000-0002-8136-5911)
- Xiaolei Chai
- Weiwei Rui
- Yuanyuan Fu (ORCID: https://orcid.org/0000-0001-7826-9403)
- Di Wu (ORCID: https://orcid.org/0000-0003-2169-8236)
- Limin Du
- Ke Quan
- Jing Sun
- Sen Zhang
- Jiacheng He
- H. Eric Xu
- Xinyu Yang
- Linlin Yang (ORCID: https://orcid.org/0000-0003-4742-2844)
- Bo Feng
Institutions
- Shanghai Jiao Tong University (CN)
- Chinese Academy of Sciences (CN)
- Hainan University (CN)
- National Medical Products Administration (CN)
- Ruijin Hospital (CN)
- Zhengzhou University (CN)
- Joint Center for Structural Genomics (US)
- General Department of Preventive Medicine (VN)
- Hainan Provincial Academy of Agricultural Sciences (CN)
- Shanghai Institute of Materia Medica (CN)
- Institute of Biomedical Science (GB)
- East China Normal University (CN)
- Hainan Medical University (CN)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-05-08
- DOI
- https://doi.org/10.1021/acs.jmedchem.5c03465
- Primary Topic
- Ferroptosis and cancer prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00